**Additional file 3: MMP3, TNF and IL-6 production after stimulation with TLR ligands (LPS, PG, TNC and MRP8) in patients and HC.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | HC (n=25) | SpA (n=50) | ERA (n=52) |
| TNF production (pg/ml) | | | |
| *Unstimulated* | *6.7(18.59)* | *28.89 (82.89)\** | *38.60 (88.29) \** |
| *LPS stimulation* | *447.42 (331.81)* | *659.52 (321.99)\** | *576.92 (273.41)\** |
| *PG stimulation* | *606.13 (245.14)* | *654 (561.93)\** | *666.99 (238.74)\** |
| *TNC stimulation* | *31.17 (43.53)* | *44.48 (92)\** | *75.488 (113.94)\** |
| *MRP8 stimulation* | *87.76 (85.74)* | *138.76 (145.28)\** | *167.34 (119.06)\** |
| IL-6 production (ng/ml) | | | |
| *Unstimulated* | *3.6 (3.2)* | *13.12 (8.06)\** | *16.49 (32.53)\** |
| *LPS stimulation* | *30.17 (11.3)* | *41.01 (30.17)\** | *35.89 (12.82)\** |
| *PG stimulation* | *35.42 (7.6)* | *49.41 (16.49)\** | *50.93 (18.76)\** |
| *TNC stimulation* | *13.9 (13.49)* | *33.10 (22.24)\** | *29.57 (24.03)\** |
| *MRP8 stimulation* | *22.38 (4.88)* | *44.26 (29.17)\** | *45.27 (29.69)\** |
| MMP3 production (pg/ml) | | | |
| *Unstimulated* | *104 (25.5)* | *280(250)\** | *35.5 (120.75)\** |
| *LPS stimulation* | *18930 (3974.5)* | *46950 (31390)\** | *60634 (20645.25)\** |
| *PG stimulation* | *17530 (6272)* | *43470 (35230)\** | *60573.5 (32587.25)\** |
| *TNC stimulation* | *1683 (791.5)* | *2150 (1560)\** | *2782 (780.5)\** |
| *MRP8 production* | *2849 (1062)* | *5340 (2100)\** | *4826.5 (1991)\** |

Results are expressed as median (IQR), \* p <0.05 compared to healthy controls (HC). Exact p values are given in figure 3. *SpA:* Spondyloarthropathy; *ERA:* Enthesitis related arthritis